Shots:

• The US FDA has granted BTD for Telix’s renal cancer imaging product TLX250-CDx (89Zr-girentuximab)
• Under BTD- the FDA will work closely with Telix to provide guidance on the development of TLX250-CDx for the diagnosis of “indeterminate renal masses” that have been identified on CT or MRI imaging
• TLX250-CDx is being developed for the purpose of determining “indeterminate renal masses” are either ccRCC or non-ccRCC- using PET imaging

 ­ Ref: PRNewswire | Image: Twitter